Animal Models and Experimental Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 3, 2024

Abstract Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 0.46% of the global population. Conventional therapeutics for RA, including disease‐modifying antirheumatic drugs (DMARDs), nonsteroidal anti‐inflammatory (NSAIDs), and corticosteroids, frequently result in unintended adverse effects. Dexamethasone (DEX) potent glucocorticoid used to treat RA due its immunosuppressive properties. Liposomal delivery DEX, particularly when liposomes are surface‐modified with targeting ligands like peptides or sialic acid, can improve drug efficacy by enhancing distribution inflamed joints minimizing toxicity. This study investigates potential liposomal systems enhance DEX treatment RA. Results from various studies demonstrate significantly inhibits progression animal models, reduces joint inflammation damage, alleviates cartilage destruction compared free DEX. The formulation also shows better hemocompatibility, fewer effects on body weight immune organ index, longer circulation time higher bioavailability. mechanism associated downregulation pro‐inflammatory cytokines tumor necrosis factor‐α (TNF‐α) B‐cell–activating factor (BAFF), which key players pathogenesis Additionally, induce expression interleukin‐10 (IL‐10), has significant immunoregulatory findings suggest represents promising candidate effective safe therapy, management this debilitating providing targeted sustained release drug.

Language: Английский